- Home
- BNTX vs BEKE Comparison
BNTX vs BEKE Comparison
Compare BNTX & BEKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTX
- BEKE
- Stock Information
- Founded
- BNTX 2008
- BEKE 2001
- Country
- BNTX Germany
- BEKE China
- Employees
- BNTX N/A
- BEKE N/A
- Industry
- BNTX Biotechnology: Biological Products (No Diagnostic Substances)
- BEKE Real Estate
- Sector
- BNTX Health Care
- BEKE Finance
- Exchange
- BNTX Nasdaq
- BEKE Nasdaq
- Market Cap
- BNTX 23.9B
- BEKE 24.7B
- IPO Year
- BNTX 2019
- BEKE 2020
- Fundamental
- Price
- BNTX $113.90
- BEKE $18.58
- Analyst Decision
- BNTX Strong Buy
- BEKE Strong Buy
- Analyst Count
- BNTX 15
- BEKE 4
- Target Price
- BNTX $143.50
- BEKE $25.97
- AVG Volume (30 Days)
- BNTX 659.5K
- BEKE 6.6M
- Earning Date
- BNTX 11-04-2024
- BEKE 11-21-2024
- Dividend Yield
- BNTX N/A
- BEKE 1.90%
- EPS Growth
- BNTX N/A
- BEKE N/A
- EPS
- BNTX N/A
- BEKE 0.50
- Revenue
- BNTX $3,390,698,192.00
- BEKE $11,766,571,657.00
- Revenue This Year
- BNTX N/A
- BEKE $13.86
- Revenue Next Year
- BNTX N/A
- BEKE $11.10
- P/E Ratio
- BNTX N/A
- BEKE $36.70
- Revenue Growth
- BNTX N/A
- BEKE 11.06
- 52 Week Low
- BNTX $76.53
- BEKE $12.44
- 52 Week High
- BNTX $131.49
- BEKE $26.05
- Technical
- Relative Strength Index (RSI)
- BNTX 48.71
- BEKE 42.44
- Support Level
- BNTX $109.52
- BEKE $17.89
- Resistance Level
- BNTX $115.34
- BEKE $18.84
- Average True Range (ATR)
- BNTX 4.24
- BEKE 0.70
- MACD
- BNTX -0.72
- BEKE -0.06
- Stochastic Oscillator
- BNTX 27.24
- BEKE 14.32
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
About BEKE KE Holdings Inc (each representing three)
KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2023, Beike's cofounders collectively control the company, while Tencent and its affiliates share 8% of voting power.